Nonhormonal alternatives to treating menopausal symptoms

American Journal of Managed Care

Volumn 4, Issue 5, 1998, Pages 732-738

  Cass, Ilana ^a,b   Runowicz, Carolyn D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Dept Obstet Gynecol Women's H ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BELLERGAL; BELLERGAL S; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CALCIUM LACTATE; CITRATE CALCIUM; CLONIDINE; ESTROGEN; ETIDRONIC ACID; GLUCONATE CALCIUM; MEGESTROL ACETATE; RALOXIFENE; TAMOXIFEN; TUMS; UNCLASSIFIED DRUG; VITAMIN D;

CONTINUING EDUCATION; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH PROMOTION; HORMONE DEFICIENCY; HOT FLUSH; HUMAN; HYPOTENSION; INSOMNIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; LIFESTYLE; MENOPAUSAL SYNDROME; NUTRITIONAL STATUS; ORAL DRUG ADMINISTRATION; PATIENT COUNSELING; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SCREENING; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION; VAGINA ATROPHY; VAGINA RING; XEROSTOMIA;

EID: 0031804114     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Andrews WC. The transitional years and beyond. Obstet Gynecol 1995;85;1-5.
2. Utian WH, Schiff I. North American Menopause Society: Gallup survey on women's knowledge, information sources and attitudes to menopause and hormone replacement therapy. JNAMS 1994:1;39-48.
3. American College of Obstetricians and Gynecologists. Precis V: An Update in Obstetrics and Gynecology. ACOG Task Force Report. Washington, DC: ACOG; 1994.
4. Leitch AM, Dodd GO, Costanza M, et al. American Cancer Society guidelines for the early detection of Breast Cancer: Update 1997. CA Cancer J Clin 1997;47:150-153.
5. Rozen P, Fireman Z, Figer A, et al. Family history of colorectal cancer as a marker of potential malignancy within a screening program. Cancer 1987:60;248-254.
6. American Cancer Society Guidelines for the Cancer-Related Health Checkup: Recommendations and rationale. CA Cancer J Clin 1980:30;208-215.
7. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogen in postmenopausal women: The Framingham Study. N Engl J Med 1987:317:1169-1174.
8. Stampfer MJ, Colditz GA, Willett WC, al. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the Nurses' Health Study. New Engl J Med 1991:325;756-762.
9. Handa VL, Landerman R, Hanlon JT, et al. Do older women use estrogen replacement? Data from the Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE). J Am Geriatr Soc 1996:44; 1-6.
10. Coope J, Marsh J. Can we improve long-term compliance with HRT? Maturitas 1992:15;151-158.
11. Koplan JP, Casperson CJ, Powell KE. Physical activity, physical fitness and health: Time to act. [editorial] JAMA 1989:262;2437.
12. Blair SH, Kohl HW 3rd, Paffenburger RS Jr, et al. Physical fitness and all-cause mortality: A prospective study of healthy men and women. JAMA 1989:262;2395-2401.
13. Haskell WL. The influence of exercise training on plasma lipids and lipoproteins in health and disease. Acta Med Scand 1986:711;25-37.
14. Noteloritz M. Exercise and health maintenance in menopausal women. In: Fant M, Kronberg F, Utian W, eds. Multidisciplinary Perspectives on Menopause. Annals of the New York Academy of Sciences. New York, NY: The New York Academy of Sciences; 1990;592:204-220.
15. Runowicz CD. Nonhormonal alternatives for menopausal women with cancer. Syllabus, Gynecologic Oncology. American College of Obstetrics and Gynecology Postgraduate Course; Cancun, Mexico 1996.
16. Hammar M, Berg G, Lindgren R. Does physical exercise influence the frequency of postmenopausal hot flushes? Obstet Gynecol Scand 1990:69;409-412.
17. Shangold M. Exercise in the menopausal woman. Obstet and Gynecol 1990:75(4S);53S-58S.
18. Heaney, RP, Recher RR, Saville PD. Menopausal changes in calcium balance performance. J Lab Clin M. 1978;92:953-963.
19. Heaney RP. Calcium supplements: Practical considerations. Osteoporosis Int 1991:1;65-71.
20. Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993:328;460-464.
21. Gass MLS. Osteoporosis and the gynecologist: A call for action. Contemp Ob/Gyn 1997:42;58-73.
22. Barbieri RL. Seven steps to the effective treatment of osteoporosis in your practice. Contemp Ob/Gyn 1998: 43;38-50.
23. Overgaard K, Riis BJ, Christiansen C and Hansen MA. Effects of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 1989:299;477-479.
24. Sood AK, Sorosky J. Alternatives to estrogen replacement therapy in the menopausal patient. Postgrad Obstet Gyncol 1996:16;1-5.
25. Ott SM, Chestnut CH. Calcitrol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 1989: 110;267-274.
26. Tilyard MW, Spears GFS, Thompson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitrol or calcium. N Engl J Med 1992:326;357-362.
27. Stewart PJ, Stern PH. Effects of the antiestrogens tamoxifen and clomiphene on bone resorption in vitro. Endocrinol 1986:118;125-131.
28. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
29. Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Adjuvant Breast and Bowel Project (NSABP B-14). J Natl Cancer Inst 1994: 86;527-537.
30. Evans GL, Bryant HU, Magee DE, Turner RT. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinol 1996:137(10);4139-4144.
31. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCL: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Min Res 1996:11;835-842.
32. Bergmans MC, Merkus JM, Corbey RS, Schellehens LA, Ubachs JM. Effect of Bellergal Retard on climacteric complaints: A double-blind, placebo-controlled study. Maturitas 1987:9;227-234.
33. Goldberg RM, Loprizini CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-158.
34. Loprizini CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flushes. N Engl J Med 1994;331:347-352.
35. Mandel FP, Geola FL, Meldrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57:133-139.
36. Baker VL. Alternatives to oral estrogen replacement. Obstet Gynecol Clin North Am 1994;21:271-297.
37. Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradial releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993;16:145-154.
38. Schimdt G, Andersson SB, Nordle O, et al. Release of 17 beta-oestrodial from a vaginal ring in postmenopausal women: Pharmacokinetic evaluation. Gynecol Obstet Invest 1994; 38:253-260.